Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company's lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc. is based in LOS ALTOS, Calif.
| Revenue (Most Recent Fiscal Year) | $0.68M |
| Net Income (Most Recent Fiscal Year) | $-36.73M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.61 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -243.13% |
| Return on Assets (Trailing 12 Months) | -119.46% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.18 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.18 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.93 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.52 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.80 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.12 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 17.66M |
| Free Float | 15.77M |
| Market Capitalization | $74.18M |
| Average Volume (Last 20 Days) | 0.47M |
| Beta (Past 60 Months) | 1.88 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.71% |
| Percentage Held By Institutions (Latest 13F Reports) | 40.42% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |